Nieuwenhuis H K, Sixma J J
Cancer. 1986 Aug 1;58(3):761-4. doi: 10.1002/1097-0142(19860801)58:3<761::aid-cncr2820580325>3.0.co;2-6.
Four patients with acute promyelocytic leukemia (APL) and clinical and laboratory manifestations of disseminated intravascular coagulation (DIC) were treated during induction chemotherapy with Org 10172 (Organon International), a low molecular weight heparinoid preparation. Plasma anti-Xa levels were maintained between 0.60 and 0.80 U/ml and anticoagulant activities, determined with a diluted activated partial thromboplastin time assay, ranged from 0.00 to 0.20 U/ml. Bleeding symptoms ceased and fibrinogen levels improved in the first week in all patients. In the second week, two patients developed bleeding as a result of primary fibrinolysis. It is concluded that Org 10172 may be useful in the treatment of patients with DIC. In patients with APL, inhibition of DIC will be insufficient to control all bleeding, since primary fibrinolysis may also occur.
4例急性早幼粒细胞白血病（APL）患者伴有弥散性血管内凝血（DIC）的临床及实验室表现，在诱导化疗期间接受了低分子量类肝素制剂Org 10172（欧加农国际公司）治疗。血浆抗Xa水平维持在0.60至0.80 U/ml之间，采用稀释活化部分凝血活酶时间测定法测定的抗凝活性范围为0.00至0.20 U/ml。所有患者在第一周出血症状停止，纤维蛋白原水平改善。在第二周，2例患者因原发性纤溶而出现出血。得出结论，Org 10172可能对DIC患者的治疗有用。在APL患者中，抑制DIC不足以控制所有出血，因为也可能发生原发性纤溶。
